2024 Truist Securities MedTech Conference
Logotype for Treace Medical Concepts Inc

Treace Medical Concepts (TMCI) 2024 Truist Securities MedTech Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Treace Medical Concepts Inc

2024 Truist Securities MedTech Conference summary

3 Feb, 2026

Market evolution and growth opportunities

  • Lapiplasty expanded Lapidus-type procedures from 15% to 30% of the U.S. bunion surgery market over several years.

  • Minimally invasive osteotomies now account for about 10% of all bunion surgeries, with 15% penetration in the osteotomy segment.

  • The company is preparing to launch two minimally invasive osteotomy platforms by late 2024, aiming for broader market coverage in 2025.

  • These new platforms target the 70% of procedures currently outside the company's portfolio, representing significant growth potential.

  • The market is experiencing increased competition, with more companies introducing Lapiplasty-like and MIS osteotomy products.

Product innovation and differentiation

  • The new minimally invasive osteotomy systems are designed to be more reproducible and easier to use, reducing the current 40-50 case learning curve.

  • Two platforms are being developed to address different surgeon philosophies and implant fixation preferences.

  • The company’s approach is to offer both a market-leading Lapidus solution and a differentiated MIS osteotomy, appealing to a wider surgeon base.

  • SpeedPlate, a new fixation option, has driven surgeon engagement and is used across existing procedures.

  • The company’s innovation strategy has been in place for years, with early IP filings covering rotational osteotomies.

Competitive landscape and strategic response

  • The market has shifted with the rapid introduction of competing Lapiplasty-like and MIS osteotomy products.

  • Surgeons are testing alternative products, changing the mix of procedures and impacting volume trends.

  • The company continues to add new active surgeons, but the frequency of Lapiplasty use per surgeon has shifted.

  • The company is responding by expanding its product suite and targeting previously untapped surgeon segments.

  • Guidance was revised after observing slower base volume in March and April, with analytics supporting the new outlook.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more